Genmab A/S (NASDAQ:GMAB) Short Interest Update

Genmab A/S (NASDAQ:GMAB) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 2,310,000 shares, a growth of 40.0% from the February 13th total of 1,650,000 shares. Currently, 0.4% of the company’s shares are short sold. Based on an average daily volume of 1,370,000 shares, the short-interest ratio is currently 1.7 days.

Genmab A/S Stock Performance

GMAB opened at $20.80 on Tuesday. The stock has a market capitalization of $13.76 billion, a P/E ratio of 11.95, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. Genmab A/S has a one year low of $18.64 and a one year high of $31.02. The business’s 50-day simple moving average is $21.22 and its 200-day simple moving average is $22.33.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, equities research analysts forecast that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. increased its holdings in shares of Genmab A/S by 94.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock valued at $636,000 after purchasing an additional 12,654 shares in the last quarter. AIMZ Investment Advisors LLC acquired a new stake in shares of Genmab A/S in the 4th quarter worth approximately $3,525,000. HighTower Advisors LLC purchased a new position in Genmab A/S in the 3rd quarter valued at approximately $273,000. Verition Fund Management LLC acquired a new position in Genmab A/S during the third quarter worth $709,000. Finally, FMR LLC boosted its position in Genmab A/S by 13.5% during the third quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after purchasing an additional 33,076 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on GMAB. Truist Financial lowered their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Finally, William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 11th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $41.33.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.